Thermo Fisher Posts 3% Q2 Rise

Thermo Fisher Scientific (NYSE:TMO), a leading provider of scientific instrumentation, reagents and consumables, and specialty diagnostics, reported its second quarter results for fiscal 2025 on July 23, 2025. The company delivered higher revenue and non-GAAP earnings per share than Wall Street estimates, with revenue (GAAP) was $10.85 billion versus the $10.68 billion analyst consensus, and Adjusted EPS was $5.36 against a $5.23 estimate. While overall revenue (GAAP) grew and product launches remained strong, profit margins again fell from last year. The quarter reflected the company’s innovation and ability to navigate a complicated policy and demand environment, despite ongoing pressures. Source: Analyst estimates for the quarter provided by FactSet. Thermo Fisher Scientific is a global science and diagnostics company serving pharmaceutical, biotechnology, healthcare, academic, and government customers. It is known for instruments, chemicals, and clinical diagnostic tools that support laboratory research, drug manufacturing, and clinical care.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool